Schwabe Stefan K.F. 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Dec 22, 2020
Insider Transaction Report
Form 4
Schwabe Stefan K.F.
Executive Vice President R&D
Transactions
- Sale
Common Stock
2020-12-21$22.10/sh−46,347$1,024,463→ 2,772 total - Exercise/Conversion
Common Stock
2020-12-21$12.98/sh+46,347$601,584→ 49,119 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2020-12-21−46,347→ 0 totalExercise: $12.98Exp: 2026-03-01→ Common Stock (46,347 underlying)
Footnotes (3)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0000 to $22.2500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vests in four equal annual installments beginning on March 1, 2017.